Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin (DP3)
Randomized Crossover Feasibility Study of Artificial Pancreas Device (AP) Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS) With and Without Basal and Insulin-to-Carbohydrate Bolus Initialization
Sponsor: Mayo Clinic
This EARLY_PHASE1 trial investigates Type 1 Diabetes Mellitus and is currently completed. Mayo Clinic leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed EARLY_PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Completed EARLY_PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Feb 2018 [monthly]
Completed EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed Phase 0
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
- Sansum Diabetes Research Institute
- University of California, Santa Barbara
- University of Padova
- University of Virginia
For direct contact, visit the study record on ClinicalTrials.gov .